IMMG Stock Overview
Immage Biotherapeutics Corp. does not have significant business operations.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Immage Biotherapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IMMG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how IMMG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IMMG performed against the US Market.
Price Volatility
| IMMG volatility | |
|---|---|
| IMMG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMG has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Zhi Cong Mou | www.immagebio.com |
Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015.
Immage Biotherapeutics Corp. Fundamentals Summary
| IMMG fundamental statistics | |
|---|---|
| Market cap | US$151.00 |
| Earnings (TTM) | -US$1.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IMMG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.83m |
| Earnings | -US$1.83m |
Last Reported Earnings
Feb 28, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IMMG perform over the long term?
See historical performance and comparison